S148: TIME-LIMITED VENETOCLAX AND IBRUTINIB FOR PATIENTS WITH RELAPSED/REFRACTORY CLL WHO HAVE UNDETECTABLE MRD – 4-YEAR FOLLOW UP FROM THE RANDOMIZED PHASE II VISION/HO141 TRIAL

• Arnon Kater,
• Julie Dubois,
• Christian Brieghel,
• Sabina Kersting,
• Lisbeth Enggaard,
• Gerrit Veldhuis,
• Rogier Mous,
• Clemens Mellink,
• Johan Dobber,
• Christian Poulsen,
• Caspar Da Cunha-Bang,
• Hendrik Fredriksen,
• Ann Janssens,
• Ida Schjodt,
• Ellen Dompeling,
• Juha Ranti,
• Mattias Mattsson,
• Mar Bellido,
• Hoa Tran,
• Kazem Nasserinejad,
• Mark-David Levin,
• Carsten Niemann

Affiliations

Arnon Kater

1 Amsterdam University Medical Centers, University of Amsterdam, Hematology, Amsterdam, The Netherlands

Julie Dubois

1 Amsterdam University Medical Centers, University of Amsterdam, Hematology, Amsterdam, The Netherlands

Christian Brieghel

2

Sabina Kersting

3 Haga Hospital (Leyweg), Den Haag, The Netherlands

Lisbeth Enggaard

4 Herlev Hospital, Herlev, Denmark

Gerrit Veldhuis

5 Antonius, Sneek, The Netherlands

Rogier Mous

6 UMC Utrecht, Utrecht, The Netherlands

Clemens Mellink

7 Amsterdam UMC, locatie AMC, Amsterdam, The Netherlands

Johan Dobber

7 Amsterdam UMC, locatie AMC, Amsterdam, The Netherlands

Christian Poulsen

8 Roskilde Sygehus, Roskilde, Denmark

Caspar Da Cunha-Bang

9 Rigshospitalet, København, Denmark

Hendrik Fredriksen

10 Odense University Hospital, Odense, Denmark

Ann Janssens

11 UZ Leuven, Leuven, Belgium

Ida Schjodt

9 Rigshospitalet, København, Denmark

Ellen Dompeling

12 Isala Zwolle, Zwolle, The Netherlands

Juha Ranti

13 Turku University Hospital, Turku, Finland

Mattias Mattsson

14 Uppsala University Hospital, Sweden

Mar Bellido

15 University Medical Center Groningen, Groningen, The Netherlands

Hoa Tran

16 Akershus University Hospital, Norway

Kazem Nasserinejad

17 Erasmus University Medical Center, Rotterdam, The Netherlands

Mark-David Levin

18 Albert Schweitzer Hospital, Dordrecht, The Netherlands

Carsten Niemann

9 Rigshospitalet, København, Denmark